相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study
Tarik Asselah et al.
LIVER INTERNATIONAL (2020)
Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection
Eric Lawitz et al.
LIVER INTERNATIONAL (2020)
Impact of Sustained Virological Response for Gastroesophageal Varices in Hepatitis-C-Virus-Related Liver Cirrhosis
Yukihisa Yuri et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Association of cholesterol uptake capacity, a novel indicator for HDL functionality, and coronary plaque properties: An optical coherence tomography-based observational study
Toshihiko Oshita et al.
CLINICA CHIMICA ACTA (2020)
Clinical impact of normal alanine aminotransferase on direct-acting antiviral outcome in patients with chronic hepatitis C virus infection
Satoru Joshita et al.
JGH OPEN (2020)
Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases
Ayumi Sugiura et al.
BIOMEDICINES (2020)
Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events
Adeel A. Butt et al.
GASTROENTEROLOGY (2019)
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
Roberta D'Ambrosio et al.
JOURNAL OF HEPATOLOGY (2019)
Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis
Patrice Cacoub et al.
GUT (2018)
Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b
Takeshi Chida et al.
GUT AND LIVER (2018)
Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis
Salvatore Petta et al.
JOURNAL OF HEPATOLOGY (2018)
Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals
Ayumi Sugiura et al.
JOURNAL OF VIRAL HEPATITIS (2018)
Risk of Acute Myocardial Infarction Among Hepatitis C Virus (HCV)-Positive and HCV-Negative Men at Various Lipid Levels: Results From ERCHIVES
Adeel A. Butt et al.
CLINICAL INFECTIOUS DISEASES (2017)
Cholesterol efflux capacity: An introduction for clinicians
Malcolm Anastasius et al.
AMERICAN HEART JOURNAL (2016)
Developmental Endothelial Locus-1 (Del-1) Inhibits Oxidized Low-Density Lipoprotein Activity by Direct Binding, and Its Overexpression Attenuates Atherogenesis in Mice
Akemi Kakino et al.
CIRCULATION JOURNAL (2016)
JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2
Yasuhiro Asahina et al.
HEPATOLOGY RESEARCH (2016)
LOX-1 in atherosclerotic disease
Tatsuya Sawamura et al.
CLINICA CHIMICA ACTA (2015)
Effect of Sofosbuvir and Ribavirin Treatment on Peripheral and Hepatic Lipid Metabolism in Chronic Hepatitis C Virus, Genotype 1-Infected Patients
Eric G. Meissner et al.
HEPATOLOGY (2015)
PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: Evidence for genotype-specific regulation of lipoprotein metabolism
Simon H. Bridge et al.
JOURNAL OF HEPATOLOGY (2015)
Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-All isoforms
Kazufumi Honda et al.
SCIENTIFIC REPORTS (2015)
Hepatitis C Virus Stimulates Low-Density Lipoprotein Receptor Expression To Facilitate Viral Propagation
Gulam Hussain Syed et al.
JOURNAL OF VIROLOGY (2014)
Hepatitis C Virus, Cholesterol and Lipoproteins - Impact for the Viral Life Cycle and Pathogenesis of Liver Disease
Daniel J. Felmlee et al.
VIRUSES-BASEL (2013)
Cholesterol Efflux and Atheroprotection Advancing the Concept of Reverse Cholesterol Transport
Robert S. Rosenson et al.
CIRCULATION (2012)
LOX Index, a Novel Predictive Biochemical Marker for Coronary Heart Disease and Stroke
Nobutaka Inoue et al.
CLINICAL CHEMISTRY (2010)
High-density lipoprotein heterogeneity and function in reverse cholesterol transport
George H. Rothblat et al.
CURRENT OPINION IN LIPIDOLOGY (2010)
A new method for measurement of total plasma PCSK9: clinical applications
Genevieve Dubuc et al.
JOURNAL OF LIPID RESEARCH (2010)
Hepatitis C Virus Infection and Its Clearance Alter Circulating Lipids: Implications for Long-Term Follow-Up
Kathleen E. Corey et al.
HEPATOLOGY (2009)
Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: A community-based study
Chia-Yen Dai et al.
JOURNAL OF HEPATOLOGY (2008)
Advantages of a single-crystal production assay to study cell culture-adaptive mutations of hepatitis C virus
Rodney S. Russell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent
Sonia Molina et al.
JOURNAL OF VIROLOGY (2008)
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice
Thomas A. Lagace et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A spectrum of PCSK9 Alleles contributes to plasma levels of low-density lipoprotein cholesterol
IK Kotowski et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Genetic variants in PCSK9 affect the cholesterol level in Japanese
K Shioji et al.
JOURNAL OF HUMAN GENETICS (2004)
分享论文
